Research
Hormonal
The use of thiazolidinediones (TZDs) in intensive glucose control strategies significantly increases the risk of heart failure, whereas gliptins (DPP-4 inhibitors) show neutral effects.
If you are on intensive diabetes treatment, the specific medication matters for your heart health. Thiazolidinediones (TZDs) are associated with a higher risk of heart failure, while gliptins appear to have a neutral effect. Ensure your doctor considers your heart failure history when prescribing these medications.
GoodQualifiesHIGH confidence
the application of thiazolidinediones (OR 1.39, 95 % CI 1.14–1.69) also increased the risk of heart failure, while the gliptins shows neutral effects to heart failure (OR 1.14, 95 % CI 0.97–1.34).
Why this rating
Meta-regression analysis of included trials.
Source
HbA1c below 7 % as the goal of glucose control fails to maximize the cardiovascular benefits: a meta-analysis
Pin Wang et al. · Cardiovascular Diabetology · 2015
DOI 10.1186/s12933-015-0285-1
Meta-analysis · 15 studiesCited 39×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →